MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 12-23-2023
Aerie Pharmaceuticals Operating Cash Flow 2011-2026 | AERI
Annual Operating Cash Flow Aerie Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -99.2 M | -64.7 M | -150 M | -153 M | -93.2 M | -79.8 M | -55.7 M | -33.7 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -33.7 M | -153 M | -91.2 M |
Quarterly Operating Cash Flow Aerie Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 61.9 M | - | - | - | -30.1 M | - | -87.1 M | -64.7 M | -41.8 M | - | -123 M | -85.1 M | -48.6 M | - | -121 M | -77.8 M | -40.8 M | - | -67.1 M | -45.8 M | -24.9 M | - | -61 M | -39.8 M | -19.4 M | - | -41.5 M | - | - | - | - | - | - | - | - | - | - | - | -12 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 61.9 M | -123 M | -51 M |
Operating Cash Flow of other stocks in the Drug manufacturers industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-12.7 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 1.19 | 3.48 % | $ 128 M |  Canada |
 |
China Pharma Holdings
CPHI
|
-466 K | $ 0.61 | -1.46 % | $ 10.7 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 3.9 | 1.56 % | $ 54.8 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 10.91 | -0.27 % | $ 559 M | USA |
 |
Harrow Health
HROW
|
3.84 M | $ 52.51 | 1.86 % | $ 1.71 B | USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Evolus
EOLS
|
-18 M | $ 4.3 | -0.69 % | $ 267 M | USA |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.44 | 2.5 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 6.04 | 0.83 % | $ 2.2 B | Canada |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.55 | 4.03 % | $ 3.37 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-51.4 M | - | - | $ 193 M | Canada |
 |
Pacira BioSciences
PCRX
|
189 M | $ 23.39 | 1.21 % | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
14.2 M | $ 4.01 | 2.42 % | $ 528 M | USA |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
363 M | $ 14.63 | 0.48 % | $ 2.01 B | USA |
 |
Aurora Cannabis
ACB
|
-211 M | $ 3.8 | 4.11 % | $ 86.3 M | Canada |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
-9.41 M | $ 0.94 | 1.95 % | $ 21.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
-51.7 M | $ 4.25 | 5.33 % | $ 128 M | USA |
 |
Tilray
TLRY
|
7.91 M | $ 7.89 | 4.44 % | $ 4.88 B | Canada |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
49.6 M | $ 12.04 | - | $ 855 M | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 2.83 | -0.35 % | $ 3.51 M | USA |
 |
Solid Biosciences
SLDB
|
-100 M | $ 6.17 | 5.11 % | $ 252 M | USA |
 |
SCYNEXIS
SCYX
|
60.2 M | $ 0.8 | 3.91 % | $ 38.3 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
Veru
VERU
|
-21.7 M | $ 2.63 | 6.05 % | $ 355 M | USA |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.25 | -1.32 % | $ 23.5 M | USA |
 |
cbdMD
YCBD
|
-353 K | $ 0.92 | 0.72 % | $ 3.97 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | USA |
 |
Viatris
VTRS
|
3 B | $ 16.15 | 1.22 % | $ 19.6 B | USA |